Document is current
Any future updates will be listed below
-
Authors
Lee, Eun Jung https://orcid.org/0000-0001-5145-4449
Kim, Museong https://orcid.org/0009-0005-0307-3963
Park, Sooyeon
Shim, Ji Hyeon
Cho, Hyun-Ju
Park, Jung Ah
Park, Kihyun
Lee, Dongeun https://orcid.org/0000-0001-8122-322X
Kim, Jeong Hwan
Jeong, Haeun https://orcid.org/0009-0000-2913-9282
Matsuzaki, Fumio https://orcid.org/0000-0001-7902-4520
Kim, Seon-Young https://orcid.org/0000-0002-1030-7730
Kim, Jaehoon
Yang, Hanseul https://orcid.org/0000-0001-5000-1675
Lee, Jeong-Soo https://orcid.org/0000-0002-8491-4429
Kim, Jin Woo https://orcid.org/0000-0003-0767-1918
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (RS-2018R1A5A1024261, RS-2022R1A2C3003589)
Korea Drug Development Fund (RS-2023-00258166)
Korea Health Industry Development Institute (RS-2024-00512384)
Korea Institute of Startup & Entrepreneurship Development
- License Information
-
More Information
Article History
Received: 9 May 2024
Accepted: 17 March 2025
First Online: 25 March 2025
Competing interests
: E.J.L, S.P., J.H.S., J.A.P., and J.W.K. are co-founders or employees of Celliaz Inc., which develops anti-PROX1 therapeutics for retinal diseases. The remaining authors declare no competing interests.
